

References

1. Bragg-Gresham J, Xu F, Han Y, et al. Epidemiology of kidney disease in the United States: Highlights from the Centers for Disease Control and Prevention Kidney Disease Surveillance System. *Clin J Am Soc Nephrol*. 2026;21(8):1456-1468. doi: 10.2215/CJN.0000000867
2. Foster MC, Levey AS, Inker LA, et al. Non-GFR determinants of low-molecular-weight serum protein filtration markers in the elderly: AGES-Kidney and MESA-Kidney. *Am J Kidney Dis*. 2017;70(3):406-414. doi:10.1053/j.ajkd.2017.03.021
3. Inker LA, Eneanya ND, Coresh J, et al. Chronic Kidney Disease Epidemiology Collaboration. New creatinine- and cystatin C-based equations to estimate GFR without race. *N Engl J Med*. 2021;385(19):1737-1749. doi: 10.1056/NEJMoa2102953.
4. St. Peter W, Bzowickyj AS, Anderson-Haag T, et al. Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consensus of the National Kidney Foundation Workgroup for implementation of race-free eGFR-based medication-related decisions. *Am J Health-Syst Pharm* 2025;82(12):644-659.
5. Centers for Medicare & Medicaid Services. *Billing and Coding: Cystatin C Measurement*. November 26, 2025. Available at: <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56988&ver=17&keyword=cystatin+c&keywordType=s&areald=all&docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CMCD%2C6%2C3%2C5%2C1%2CF%2CP&contractOption=all&sortBy=relevance&bc=1>
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16(1):31-41.
7. Zarowitz BJ, Van C, Semla TP. The NKF has spoken: Now, what's a clinician to do? *J Am Geriatr Soc*. 2026. <http://doi.org/10.1111/jgs.70280>
8. Williams VL, Gerlach AT. Establishing discordance rate of estimated glomerular filtration rate between serum creatinine-based calculations and cystatin-C-based calculations in critically ill patients. *Pharmacother* 2025;45:161-168. doi: 10.1002/phar.70000
9. NEURONTIN. Nih.gov. Accessed November 10, 2025. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388>
10. Oh G, Moga DC, Fardo DW, Abner EL. The association of gabapentin initiation and neurocognition changes in older adults with normal cognition. *Front Pharmacol*. 2022;13:910719. doi: 10.3389/fphar.2022.910719.

11. Center for Drug Evaluation and Research, US Food and Drug Administration. Pharmacokinetics in patients with impaired renal function – study design, data analysis, and impact on dosing (guidance for industry). Published online March 15, 2024. <https://www.fda.gov/media/78573/download>

12. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med* 2012;367:20-29. doi: 10.1056/NEJMoa1114248